The Oncology Institute's earnings before interest and taxes (EBIT) for the
three
months ended in Mar. 2026 was $-0.6 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-36.0 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
The Oncology Institute's annualizedROC % for the quarter that ended in Mar. 2026 was -31.92%.
The Oncology Institute's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -4.72%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
The Oncology Institute's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -6.15%.
The Oncology Institute (NAS:TOI) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
The Oncology Institute's annualizedROC % for the quarter that ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, The Oncology Institute's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Oncology Institute EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, The Oncology Institute's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where The Oncology Institute's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Oncology Institute (TOI) has a EBIT of $-36.0 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on The Oncology Institute.
Is The Oncology Institute's EBIT too high?
The Oncology Institute's current EBIT is $-36.0 Mil. Overall, The Oncology Institute has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does The Oncology Institute's EBIT compare to CCRN and SRTA?
The Oncology Institute's EBIT of $-36.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on The Oncology Institute. The Oncology Institute's current EBIT is $-36.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Oncology Institute stock overvalued right now?
Based on GuruFocus' analysis, The Oncology Institute (TOI) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.24, compared to a current price of $5.11 — trading 127.9% above its estimated fair value. The current EBIT is $-36.0 Mil. The Oncology Institute's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For The Oncology Institute (TOI), the current EBIT is $-36.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Oncology Institute (TOI) Overvalued in 2026?
Based on GuruFocus' analysis, The Oncology Institute stock appears to be overvalued.
The current stock price of $5.11 is trading 127.9% above its estimated GF Value™ of $2.24.
GuruFocus considers The Oncology Institute to be Significantly Overvalued.
Key valuation signals for TOI:
EBIT: $-36.0 Mil
GF Value™: $2.24 vs. price of $5.11 (127.9% above fair value)
No single metric tells the full story. See the TOI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
56GF Score
Get the complete analysis for TOI
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TOI has been successfully added to your 
